MX2024006942A - Composicion farmaceutica que comprende salbutamol. - Google Patents

Composicion farmaceutica que comprende salbutamol.

Info

Publication number
MX2024006942A
MX2024006942A MX2024006942A MX2024006942A MX2024006942A MX 2024006942 A MX2024006942 A MX 2024006942A MX 2024006942 A MX2024006942 A MX 2024006942A MX 2024006942 A MX2024006942 A MX 2024006942A MX 2024006942 A MX2024006942 A MX 2024006942A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
canister
salbutamol
relates
metered
Prior art date
Application number
MX2024006942A
Other languages
English (en)
Spanish (es)
Inventor
Isabelle Peyron
Irene Rossi
Ségolène Sarrailh
Original Assignee
Aptar France Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptar France Sas filed Critical Aptar France Sas
Publication of MX2024006942A publication Critical patent/MX2024006942A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2024006942A 2021-12-20 2022-12-19 Composicion farmaceutica que comprende salbutamol. MX2024006942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2113999A FR3130554B1 (fr) 2021-12-20 2021-12-20 Composition pharmaceutique comprenant du salbutamol
PCT/FR2022/052421 WO2023118717A1 (fr) 2021-12-20 2022-12-19 Composition pharmaceutique comprenant du salbutamol

Publications (1)

Publication Number Publication Date
MX2024006942A true MX2024006942A (es) 2024-09-10

Family

ID=80595325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006942A MX2024006942A (es) 2021-12-20 2022-12-19 Composicion farmaceutica que comprende salbutamol.

Country Status (9)

Country Link
US (1) US20250041244A1 (enExample)
EP (1) EP4452227B1 (enExample)
JP (1) JP2024546201A (enExample)
CN (1) CN118510492A (enExample)
AU (1) AU2022420913A1 (enExample)
CA (1) CA3238932A1 (enExample)
FR (1) FR3130554B1 (enExample)
MX (1) MX2024006942A (enExample)
WO (1) WO2023118717A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250281404A1 (en) * 2024-03-07 2025-09-11 Recipharm Laboratories, Inc. Composition for use in pressurised dispensing container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020204A2 (en) * 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition

Also Published As

Publication number Publication date
FR3130554A1 (fr) 2023-06-23
CN118510492A (zh) 2024-08-16
WO2023118717A1 (fr) 2023-06-29
CA3238932A1 (fr) 2023-06-29
AU2022420913A1 (en) 2024-05-23
FR3130554B1 (fr) 2024-10-18
EP4452227B1 (fr) 2025-11-26
EP4452227A1 (fr) 2024-10-30
US20250041244A1 (en) 2025-02-06
EP4452227C0 (fr) 2025-11-26
JP2024546201A (ja) 2024-12-18

Similar Documents

Publication Publication Date Title
CA2474479A1 (en) Composition for inhalation
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
DK0616525T3 (da) Medikamenter
CA2125666A1 (en) Medicaments
GB9425160D0 (en) Medicaments
RU94030722A (ru) Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеваний
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BG104720A (en) Aerosolized active agent delivery
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
MY129281A (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of a acute condition of asthma
MX2022012359A (es) Formulacion.
JP2024515446A5 (enExample)
MX2024015613A (es) Composicion farmaceutica que comprende salbutamol
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
Schultze-Werninghaus Multicenter 1-year trial on formoterol, a new long-acting β 2-agonist, in chronic obstructive airway disease
US10383883B2 (en) Treatment of congestion using steroids and adrenergics
JP2004529108A5 (enExample)
EP1915166B1 (en) Marrubiin and composition for reducing snoring, package and method
Pedersen et al. Powder administration of pure budesonide for the treatment of seasonal allergic rhinitis
FR3130554B1 (fr) Composition pharmaceutique comprenant du salbutamol
US20060210482A1 (en) Chemical composition and method for cold and sinus relief
Newman et al. Nebulisers: uses and abuses
Buhl et al. P256 Safety Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat In Chronic Obstructive Pulmonary Disease In Two 1-year Studies